After the "glass glue war," GIANT BIOGENE shows its first signs of growth anxiety
Wallstreetcn·- In mid-2025, a public controversy involving Gigi Biological and Huaxi Biological escalated tensions, impacting Gigi's flagship collagen brand, Kefu Mei, over claims of misrepresented collagen content. - Despite a slight revenue decline to 55.18 billion yuan and a net profit drop of 7.15%, Kefu Mei saw a 1.6% decrease in sales, while another brand, Keli King, experienced a 9.2% growth, attributed to online expansion. - Looking ahead to 2026, Gigi Biological aims to regain growth through enhanced medical aesthetics business and new product developments, following a year of challenges that revealed shortcomings in product standards.CIIE Direct Hit: AI Reshapes the Health Ecosystem
Wallstreetcn·- The 8th China International Import Expo opened on November 5, showcasing innovations in the health industry, particularly through AI integration. - Key collaborations, such as between YaoSu Technology and Medici, highlight AI's role in enhancing drug development efficiency and precision in health services. - As AI continues to evolve, it is set to transform the health ecosystem, making services more accessible and effective, while driving significant advancements in the industry.